Group 1 - ST Zhongzhu (SH 600568) held its 12th meeting of the 10th Board of Directors on October 27, 2025, via teleconference to discuss the proposal for the third extraordinary shareholders' meeting of 2025 [1] - For the first half of 2025, ST Zhongzhu's revenue composition was as follows: hospital income accounted for 56.92%, real estate projects 25.88%, pharmaceutical industry 8.93%, medical devices 4.15%, and center cooperation 3.59% [1] - As of the report date, ST Zhongzhu's market capitalization was 4 billion yuan [1] Group 2 - The news also mentions a private shipping tycoon taking over Shanshan Group, indicating potential complexities in the restructuring process and the emergence of a mysterious figure in the consortium [1]

证券代码：600568 证券简称：ST 中珠 公告编号：2025-052 号 2025 年 10 月 15 日，公司收到董事、提名委员会委员、常务副总裁陈江先 生的书面辞职报告。陈江先生因个人原因辞去公司董事、董事会提名委员会委员、 常务副总裁职务，辞职后不再担任公司任何职务。具体内容详见公司于 2025 年 10 月 16 日披露的《中珠医疗控股股份有限公司关于公司董事、高级管理人员离 任的公告》（公告编号：2025-050 号）。 二、公司股东提名的情况 2025 年 10 月 20 日，公司董事会收到合计持股 10%以上股东——广州云鹰资 本管理有限公司（以下简称"云鹰资本"）、股东黄鹏斌先生联合送达的《关于提 请召开中珠医疗控股股份有限公司临时股东会审议补选董事的请求函》（以下简 称"《请求函》"）。 中珠医疗控股股份有限公司 关于补选公司第十届董事会非独立董事的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）于 2025 年 10 月 2 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-053 号 中珠医疗控股股份有限公司 关于召开2025年第三次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 召开的日期时间：2025 年 11 月 12 日 10 点 00 分 召开地点：珠海市情侣南路 1 号仁恒滨海中心 5 座 8 层 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 重要内容提示： 一、召开会议的基本情况 (一)股东会类型和届次 2025年第三次临时股东会 (二)股东会召集人：董事会 (三)投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合的方 式 (四)现场会议召开的日期、时间和地点 网络投票起止时间：自2025 年 11 月 12 日 至2025 年 11 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为 ...

中珠医疗控股股份有限公司 ZhongZhu Healthcare Holding Co.，Ltd 2025 年第三次临时股东会 会议资料 二〇二五年十一月十二日 中国·珠海 2025 年第三次临时股东会会议资料 目 录 - 2 - 一、2025 年第三次临时股东会会议议程 二、2025 年第三次临时股东会会议须知 三、2025 年第三次临时股东会表决办法 四、会议议案 1、审议《关于补选公司第十届董事会非独立董事的议案》； 2025 年第三次临时股东会会议资料 中珠医疗控股股份有限公司 2025 年第三次临时股东会会议议程 时 间：二〇二五年十一月十二日 上午 10:00 地 点：珠海市情侣南路 1 号仁恒滨海中心 5 栋 8 层 主持人：董事长陈旭先生 会议议程： 一、主持人宣布现场会议开始。 二、宣读 2025 年第三次临时股东会会议须知。 三、宣读 2025 年第三次临时股东会表决办法。 四、报告出席现场会议的股东人数及其代表的股份总数。 五、推选 2025 年第三次临时股东会现场表决监票人。 六、对下列议案进行审议： 1、审议《关于补选公司第十届董事会非独立董事的议案》； 七、股东发言及回答股东提问。 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-051 号 中珠医疗控股股份有限公司 第十届董事会第十二次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）第十 届董事会第十二次会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 2、本次董事会会议于 2025 年 10 月 22 日以邮件、电话、微信送达方式发 出通知。 3、本次董事会会议于 2025 年 10 月 27 日以通讯会议的方式召开。 二、董事会会议审议情况 经与会董事认真审议，通过以下议案： （一）审议通过《关于股东提请召开临时股东会审议补选非独立董事的议 案》； 表决结果：同意 8 票，反对 0 票，弃权 0 票。 2025 年 10 月 20 日，公司董事会收到合计持股 10%以上股东——广州云鹰 资本管理有限公司（以下简称"云鹰资本"）、股东黄鹏斌先生联合送达的《关 于提请召开中珠医疗控股股份有限公司临时 ...

Market Overview - On October 23, the medical services sector rose by 0.19% compared to the previous trading day, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 71.15, up 5.27% with a trading volume of 11,500 lots and a transaction value of 799.13 million [1] - ST Zhongzhu (600568) closed at 2.02, up 5.21% with a trading volume of 400,000 lots and a transaction value of 794.03 million [1] - Other notable gainers include *ST Biology (000504) at 9.50, up 2.48%, and Kanglong Chemical (300759) at 31.44, up 1.55% [1] Top Losers in Medical Services - Haitai Bio (300683) closed at 32.06, down 7.15% with a trading volume of 136,900 lots and a transaction value of 440 million [2] - Innovative Medical (002173) closed at 22.32, down 5.10% with a trading volume of 639,200 lots and a transaction value of 143.2 million [2] - Other significant decliners include Chengda Pharmaceutical (301201) at 32.70, down 3.77%, and Heyuan Bio (688238) at 7.49, down 2.60% [2] Capital Flow Analysis - On the same day, the medical services sector experienced a net outflow of 637 million from institutional investors, while retail investors saw a net inflow of 723 million [2][3] - The overall capital flow indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2][3] Individual Stock Capital Flow - For Aier Eye Hospital (300015), there was a net outflow of 20.59 million from institutional investors, while retail investors contributed a net inflow of 231,940 [3] - Kanglong Chemical (300759) saw a net inflow of 17.04 million from institutional investors, but a net outflow of 2.59 million from retail investors [3] - Bid Pharma (688073) had a net inflow of 1.08 million from institutional investors, while retail investors contributed a net inflow of 504,580 [3]

Core Insights - The Chinese liquor industry is shifting from a focus on high-end products to a more consumer-oriented approach, with an emphasis on affordability and practicality, particularly in the light bottle segment [1][3] - Niulanshan's Chenxiang series has emerged as a leading representative of this trend, embodying the philosophy of "brewing for the people" and achieving significant market penetration [1][8] Industry Trends - The white liquor market is experiencing a transition towards rational consumption, with consumers prioritizing practical needs over brand prestige and packaging [3][8] - The demand for high-cost performance products is becoming a key driver of growth in the industry, with Niulanshan's Chenxiang series exemplifying this shift [3][8] Company Performance - Niulanshan's Chenxiang series has achieved cumulative sales of 6 billion bottles over the past decade, leading the national market in both volume and sales [3][4][5] - The brand has received recognition from Shangpu Consulting for its market leadership in the light bottle segment, highlighting its strong consumer acceptance [3][4] Product Characteristics - The Chenxiang series is designed to meet everyday consumer needs, featuring cost-effective pricing and flexible packaging options suitable for various social settings [8][9] - The product's quality is enhanced through a combination of traditional brewing techniques and modern microbiological fermentation, ensuring a rich flavor profile [9][11] Marketing Initiatives - Niulanshan has launched initiatives such as the "Jinbiao Niu Smoke and Fire Restaurant List" in collaboration with Alibaba's ecosystem, aimed at promoting local dining experiences and enhancing brand visibility [13] - These marketing efforts have resulted in significant exposure and engagement, aligning the brand with contemporary consumer preferences for quality and affordability [13]

Group 1 - The core point of the announcement is the resignation of Mr. Chen Jiang from his positions as a director, member of the nomination committee, and executive vice president of Zhongzhu Medical Holdings Co., Ltd. due to personal reasons [2][3] - Mr. Chen's resignation is effective immediately upon delivery of his resignation report to the board, and it will not affect the board's operation or the company's normal business [3] - The company will complete the necessary procedures for the election of new directors and members of the nomination committee to ensure the integrity of its governance structure [3][4] Group 2 - The second extraordinary general meeting of shareholders was held on October 15, 2025, with no resolutions being rejected [6][8] - The meeting was legally convened and conducted, with a combination of on-site and online voting methods [8] - All proposed resolutions, including amendments to the company's articles of association and management systems, were approved by the shareholders [9][10]

（记者 贾运可） 每经头条（nbdtoutiao）——出租白银的爆赚机会：年化利率飙升到35%，全球白银正空运往英国套 利，背后是一场史诗级逼空 每经AI快讯，ST中珠10月15日晚间发布公告称，公司董事会于2025年10月15日通过快递形式收到公司 董事、提名委员会委员、常务副总裁陈江先生的书面辞职报告。陈江先生因个人原因辞去公司董事、董 事会提名委员会委员、常务副总裁职务，辞职后不再担任公司任何职务。 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-050 号 中珠医疗控股份有限公司 关于公司董事、高级管理人员离任的公告 特别提示 (一)提前离任的基本情况 | 姓名 | 离任职务 | | 原定任期到 | | 是否继续在上 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | | | | 离任时间 | 期日 | 离任原因 | 市公司及其控 股子公司任职 | 履行完毕的 公开承诺 | | 陈江 | 董事、董事会提名 委员会委员、常务 | 2025 年 10 | 2027 年 12 | 个人原因 | 否 | 否 | | | | 月 15 日 | 月 5 日 | | | | | | 副总裁 | | | | | | (二)离任对公司的影响 根据《中华人民共和国公司法》《公司章程》等有关规定，陈江先生的辞职 报告自送达公司董事会之日起生效，其辞职不会导致董事会成员低于法定人数， 陈江先生已按公司相关规定做好交接工作，其离任不会影响董事会运作和公司正 常经营。公司将按照相关法定程序完成董事及董事会提名委员会委员的补选工作， 保证公司治理结构完整，并及 ...